EvoGenix will work with the NIH under a CRADA to provide tailored antibodies against PAMP, a small protein shown to be a vital factor in angiogenesis. “It appears that PAMP-related proteins act earlier in blood vessel formation than the target for Avastin, VEGF,” explains Alfredo Martinez, Ph.D., of the Cajal Institute, “so that inhibitory antibodies provided by EvoGenix may provide broader suppression than Avastin of new blood vessel growth."
Scientists at the NCI will carry out testing and initial clinical evaluation of these new anticancer therapeutics. EvoGenix says that it was selected as the partner for the NCI team because of its ability to produce highly potent humanized antibodies suitable for therapeutic testing.
"Imminent testing of our antibodies by the NCI team will confirm the value of this new approach to cancer therapy," explains Steffen Nock, president of the EvoGenix U.S. operations.